Vision UK 2013 speakers announced

Article

The Vision UK 2013 conference, on the 11 June, has confirmed several key speakers, announced the UK Vision Strategy.

The Vision UK 2013 conference, on the 11 June, has confirmed several key speakers, announced the UK Vision Strategy.

The speakers include UK experts in eye health, social care and sight loss, as well as directors of leading sight loss charities. Notable speakers will be Dr Clare Gerada, Chair for the Royal College of General Practitioners, Lesley-Anne Alexander CBE, the Chief Executive RNIB and Chair of UK Vision Strategy and Parul Desai from Moorfields Eye Hospital.

Anna Lightstone, UK Vision Strategy Programme Director and VISION 2020 UK Interim Chief Operations Officer, stated, "Vision UK 2013 is about 'progress through partnership'– working with our partners and supporters to make real changes with eye care and sight loss across the UK. Our partners have been central to the development of the refreshed Strategy and now we would like their help in turning it into a reality over the next five years."

The conference is expected to play host to over 400 delegates from across the UK health, social care and voluntary sectors and will launch the refreshed UK Vision Strategy for 2013-2018.

Please visit the Vision 2020 UK website for more details.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.